Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

NCT07494305 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar I Disorder

Interventions

DRUG: LB-102
OTHER: Placebo

Sponsor

LB Pharmaceuticals Inc.